Firethorn Wealth Partners, LLC Point Biopharma Global Inc. Transaction History

Firethorn Wealth Partners, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 17, 2023	SELL	$6.67 - $9.71 $4,669 - $6,797	-700 Reduced 3.12%	21,705 $144,000
Q2 2023 Aug 01, 2023	SELL	$6.86 - $10.86 $34,128 - $54,028	-4,975 Reduced 18.17%	22,405 $202,000
Q1 2023 May 02, 2023	SELL	$6.78 - $8.1 $57,799 - $69,052	-8,525 Reduced 23.74%	27,380 $199,000
Q4 2022 Feb 07, 2023	BUY	$5.72 - $9.78 $1,144 - $1,955	200 Added 0.56%	35,905 $261,000
Q3 2022 Oct 18, 2022	SELL	$7.24 - $10.31 $11,041 - $15,722	-1,525 Reduced 4.1%	35,705 $276,000
Q2 2022 Aug 03, 2022	BUY	$5.6 - $9.5 $19,488 - $33,060	3,480 Added 10.31%	37,230 $271,000
Q1 2022 May 03, 2022	BUY	$5.46 - $8.13 $11,193 - $16,666	2,050 Added 6.47%	33,750 $269,000
Q4 2021 Feb 08, 2022	BUY	$4.83 - $9.75 $153,111 - $309,075	31,700 New	31,700 $178,000

20K

Ticker PNT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 104,025,000
Description
POINT Biopharma Global Inc., a radiopharmaceutical company, focuses on the development and commercialization of radioligands that fight cancer. Its lead product candidates include PNT2002, a prostate-specific membrane antigen (PSMA) targeted radioligand that is in Phase III trial for the treatment of metastatic castration-resistant prostate canc...

Get notified when there are updates to the investment portfolio of Firethorn Wealth Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Firethorn Wealth Partners, LLC with notifications on news.